drugset
Drugs / Short ragweed pollen allergen extract
last change Nov 2018 re-read 3 minutes ago

Short ragweed pollen allergen extract

Protein / enzyme biologic

Developed for
seasonal allergic rhinitis
Investigated by
Merck Sharp & Dohme LLC

Trials 1

today NCT02478398 · Ph 3
201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT02478398 Jul 2015 → Nov 2018 seasonal allergic rhinitis Merck Sharp & Dohme LLC Completed Met primary

Press releases naming this drug 2 releases

DateIssuerRelease
2014-04-17 Merck Sharp & Dohme LLC FDA Approves Merck’s RAGWITEK™ (Short Ragweed Pollen Allergen Extract) Sublingual Tablet as Immunotherapy to Treat Short Ragweed Pollen-Induced Allergic Rhinitis with or without Conjunctivitis in Adults merck.com ↗
2014-01-28 Merck Sharp & Dohme LLC Merck Statement on FDA Advisory Committee Meeting for RAGWITEK™ (Short Ragweed Pollen Allergen Extract), an Investigational Sublingual Allergy Immunotherapy Tablet merck.com ↗

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Short ragweed pollen allergen extract ClinicalTrials.gov intervention name — accepted as the source's own label NCT02478398 ↗
Modality Protein / enzyme biologic “Biological: Short ragweed pollen allergen extract” NCT02478398 ↗
Route Other “One sublingual tablet containing 12 units of Amb a 1-U, once daily (QD) for up to 35 weeks.” NCT02478398 ↗